Special Issue "Circulating Tumor Cells"
Deadline for manuscript submissions: closed (30 June 2016)
Prof. Dr. Dario Marchetti
Director, Center of the Biomarker Research Program at Houston Methodist Research Institute, and Professor of Pathology and Genomic Medicine at Methodist Hospital, MS: R7-102, 6670 Bertner Avenue, Houston, TX 77030, USA
Website | E-Mail
Interests: the biology and therapeutic utility of circulating tumor cells (CTCs); mechanisms of brain metastasis; breast cancer dormancy; roles of heparanase in development and disease
The major cause of patient mortality in cancer is metastasis, however, understanding of the metastatic cascade and mechanisms underlying this complex set of events remain poorly understood. Cancer cells invade the surrounding tissue of primary or metastatic tumors, intravasate into lymphatic and blood vessels, disseminate to distant tissues, extravasate by adapting to the new microenvironment, and colonize these tissues. Because dissemination mostly occurs through the blood, circulating tumor cells (CTCs) are of paramount importance and one of the most promising areas of oncology research. CTCs might serve as “liquid biopsy” as a better way to diagnose cancer patients compared to painful biopsies of the primary tumor, and can represent a clinically useful tool to better reflect cancer progression and monitoring in the patient.
The isolation, characterization, and interrogation of CTCs are hampered by their rarity and heterogeneity, either inherited from respective primary or metastatic tumors or as a result of CTC evolution in blood by genetic/epigenetic progression that may or may not lead to a fully metastatic-competent CTC. Significant technical challenges in the field also persist in regard to identifying and interrogating CTC heterogeneity, assessing CTC biomarkers of clinical utility, and comprehensively capturing these cells (usually, a ratio of one CTC per 106 leukocytes and 109 erythrocytes in one milliliter of blood). Finally, many studies have reported the clinical impact of enumerating CTCs, considering that CTC testing is being employed in over 300 clinical trials worldwide. However, much of the CTC biology needs to be discovered and many scientific/technical challenges must be overcome before their clinical promise as biomarkers and targets for improved therapies can be fulfilled.
The objective of this Special Issue is to publish the latest findings in CTC research and clinical implementation. Contributions outlining CTC discoveries in biological and clinical settings, CTC theoretical and pre-clinical models, CTC technologies and methods for their detection, and clinical findings applying CTC concepts, are welcome.
Prof. Dr. Dario Marchetti
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed Open Access monthly journal published by MDPI.
- circulating tumor cells
- liquid biopsy
- cancer metastasis
- minimal residual disease
- early-detection of cancer
- cancer diagnostics
- CTC technologies and platforms
- CTC biology
- CTC clinical intervention
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Clinical Application of CTCs in Prostate Cancer: from the Bench to the Bedside and Back
Authors: Laura Muinelo Romay, Luis Ángel León Mateos and Maria Vieito
Abstract: Prostate cancer (PCa) is the most common cancer in men worldwide. To improve future drug development and patient management for patients with PCa, surrogate biomarkers associated with relevant outcomes are required. Circulating tumor cells (CTCs) are tumor cells with the ability to enter the circulatory system, being the principal responsible for the development of metastases at distant organs. In recent years, their detection has gained interest as surrogate biomarker. Clinical studies have revealed that high levels of CTCs in blood are correlated with disease progression in PCa, however, their predictive value for therapeutic response monitoring is less demonstrated. Despite, the important progress in the clinical development of CTCs, critical requirements should achieved for the implementation of their analysis as a routine oncology tool. The goal of the present review is to provide an update on the advances for the clinical validation of CTCs as a surrogate biomarker in PCa, discussing the principal obstacles and the main challenges for their inclusion in the clinical practise.
Title: Circulating Tumor Cells as a Potential Therapeutic Target for Cancer Patients
Author: Galatea Kallergi
Title: Clinical Implications and Future Perspectives of Circulating Tumor Cells in Clinical Outcome of Colorectal Cancer
Author: Jaw-Yuan Wang
Title: KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients
Authors: Susana Olmedillas López1*, Dolores C. García-Olmo2, Mariano García-Arranz1,3, Héctor Guadalajara 3,4, Carlos Pastor 5, Damián García-Olmo1,3,5
Affiliations: 1 Health Research Institute-Fundación Jiménez Díaz University Hospital (IIS-FJD). Madrid, Spain; email@example.com (S.O.L.); firstname.lastname@example.org (M.G.A.) ; email@example.com (D.G.O.)
2 Experimental Research Unit, General University Hospital of Albacete, Albacete, Spain; firstname.lastname@example.org
3 Department of Surgery, School of Medicine, Autónoma University of Madrid, Madrid, Spain
4 Department of General Surgery. General Hospital of Villalba, Madrid, Spain; email@example.com
5 Department of Surgery, Fundación Jiménez Díaz University Hospital, Madrid, Spain; firstname.lastname@example.org
* Correspondence: email@example.com; Tel.: +34-91-550-4800 (3398)
Abstract: KRAS mutations are responsible for resistance to anti-EGFR therapy in colorectal cancer patients. These mutations sometimes appear once treatment has started. Detection of KRAS mutations in circulating cell-free DNA in plasma (‘liquid biopsy’) by droplet digital PCR (ddPCR) has emerged as a very sensitive and promising alternative to serial biopsies for disease monitoring. In this study, KRAS G12V mutation was analyzed by ddPCR in plasma DNA from 10 colorectal cancer patients and compared to 6 healthy donors. The percentage of KRAS G12V mutation relative to wild-type sequences in tumor-derived DNA was also determined. KRAS G12V mutation circulating in plasma was detected in 9 of 10 colorectal cancer patients whose tumors were also mutated. Colorectal cancer patients had 35.62 copies of mutated KRAS/mL plasma, whereas in healthy controls only residual copies were found (0.62 copies/mL, p=0.0066). Interestingly, patients with metastatic disease showed a significantly higher number of mutant copies than M0 patients (126.25 vs 9.37 copies/mL, p=0.0286). Wild-type KRAS was also significantly elevated in colorectal cancer patients compared to healthy controls (7718.8 vs 481.25 copies/mL, p=0.0002). In conclusion, KRAS G12V mutation is detectable in plasma of colorectal cancer patients by ddPCR and could be used as a non-invasive biomarker.
Keywords: KRAS; colorectal cancer; plasma; droplet digital PCR; circulating cell-free DNA